The benefits of once-daily combination single-inhaler therapy in asthma: Professor Ken Chapman

Sponsored by Novartis Pharmaceuticals Australia Pty Ltd

The recent PLATINUM clinical trial program1-4 evaluated the efficacy and safety of the Atectura Breezhaler (indacaterol/mometasone furoate) and Enerzair Breezhaler (indacaterol/glycopyrronium bromide/mometasone furoate) in four large clinical trials of various asthma patient populations. The limbic spoke to Professor Kenneth Chapman from the University of Toronto about what the results of the PLATINUM program tell us ...

Already a member?

Login to keep reading.

© 2021 the limbic